Oral Micronized Progesterone: Restarting After Acute Illness

What Oral Micronized Progesterone Actually Does

Oral micronized progesterone is bioidentical to endogenous progesterone. It binds the nuclear progesterone receptor to oppose estrogen-driven endometrial proliferation, which is its core clinical role in postmenopausal hormone therapy. The peanut-oil suspension in each Prometrium capsule allows intestinal absorption that plain crystalline progesterone cannot achieve [1].

After a 200 mg oral dose, peak serum progesterone (Cmax) reaches roughly 17 ng/mL at 2 to 3 hours, dropping to near-baseline by 24 hours [2]. This short residence time means a single missed dose does not create sustained progesterone deficiency, but a multi-day interruption during an acute illness can leave the endometrium relatively unopposed if estrogen therapy was continued throughout.

Hepatic First-Pass and Metabolite Profile

Oral progesterone undergoes extensive first-pass hepatic metabolism, generating several 5-alpha and 5-beta reduced metabolites [2]. Allopregnanolone, a potent positive allosteric modulator of GABA-A receptors, produces the well-known sedative effect many patients notice within 1 to 2 hours of the bedtime dose [3]. Acute liver inflammation or severe hepatic dysfunction lengthens the half-life of these metabolites and raises the risk of excessive CNS sedation on restart.

Endometrial Protection Evidence

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial (N=875, 3 years) demonstrated that cyclic oral micronized progesterone 200 mg for 12 days per month provided endometrial protection statistically equivalent to medroxyprogesterone acetate (MPA) while producing a more favorable HDL-cholesterol profile than MPA [4]. The Endocrine Society's 2022 clinical practice guidelines on menopausal hormone therapy cite PEPI as foundational evidence for recommending oral micronized progesterone as a first-line progestogen for endometrial protection [5].

Why Acute Illness Interrupts Progesterone Therapy

Acute illness disrupts oral hormone therapy through several overlapping mechanisms. Nausea and vomiting reduce bioavailability. Fever increases hepatic blood flow and can accelerate first-pass metabolism. Some acute infections trigger systemic inflammation that transiently alters steroid-binding globulin concentrations [6].

Absorption Disruption

Because Prometrium relies on intestinal fat absorption via its peanut-oil base, any condition causing significant GI dysmotility, malabsorption, or vomiting effectively reduces delivered dose. A 2019 pharmacokinetic review in the Journal of Clinical Pharmacology confirmed that co-administration of oral progesterone with food increases AUC by approximately 2.5-fold compared with fasting, meaning illness-related anorexia alone could meaningfully reduce systemic exposure [2].

Venous Thromboembolism Considerations

Oral micronized progesterone carries a substantially lower VTE risk than synthetic progestogens. The E3N French cohort study (N=80,377 woman-years) found that oral progesterone combined with transdermal estrogen was not associated with elevated VTE risk, unlike oral estrogen plus synthetic progestins [7]. During acute illness, however, immobility and dehydration independently raise VTE risk. If a patient was admitted to hospital, VTE risk stratification should precede progesterone restart, though progesterone itself does not compound that risk the way older synthetic progestogens do [7].

Hepatic and Renal Illness

Acute hepatitis (viral, alcoholic, or drug-induced) reduces CYP3A4 activity, slows progesterone clearance, and may intensify the sedative allopregnanolone effect [3]. Acute kidney injury does not directly impair progesterone metabolism because the drug is hepatically cleared, but it may alter protein binding and free-fraction availability. The FDA-approved Prometrium prescribing information explicitly lists known or suspected hepatic disease as a contraindication [1].

Clinical Criteria for Safe Restart

Before resuming oral micronized progesterone after any acute illness, four clinical criteria should be met. Each criterion is binary, not graded.

Criterion 1: Oral Medication Tolerance

The patient must be tolerating other oral medications without vomiting for at least 24 hours. Because Prometrium's bioavailability is food-dependent, a patient still unable to eat a small amount of food at bedtime will not achieve therapeutic progesterone levels even at a full dose.

Criterion 2: Hemodynamic Stability

Sepsis, distributive shock, or any hemodynamically unstable state is not a setting in which elective hormone therapy restart is appropriate. Once the patient is off vasopressors and maintaining a mean arterial pressure above 65 mmHg without support, this criterion is met.

Criterion 3: No Active Contraindication

The prescriber should confirm absence of:

• Active VTE (deep vein thrombosis or pulmonary embolism diagnosed during the illness)
• Acute hepatic failure or transaminases greater than 3x the upper limit of normal
• New undiagnosed abnormal uterine bleeding that emerged during the illness
• Known or newly discovered hormone-sensitive malignancy

The FDA prescribing information for Prometrium lists these as absolute contraindications [1].

Criterion 4: Interruption Duration Under 30 Days

An interruption of fewer than 30 days in a continuous combined regimen generally does not require endometrial biopsy before restarting. An interruption exceeding 30 days in a patient on concurrent estrogen therapy should prompt discussion of whether a short course of 14-day cyclic progesterone is warranted before returning to the continuous 100 mg nightly schedule, to clear any proliferative changes that may have accumulated [5].

Restart Dosing Protocol

The following restart framework is derived from synthesis of the Endocrine Society guidelines, the FDA label, and the PEPI pharmacodynamic data. It is intended as a clinical reference pending physician sign-off.

Continuous Combined Regimen (100 mg Nightly)

For patients on continuous combined HRT who interrupted for fewer than 14 days, resume 100 mg orally at bedtime on the same night the oral-tolerance criterion is met. No loading dose is needed. Allopregnanolone levels re-establish within one dosing cycle [3].

For interruptions of 14 to 30 days, resume 100 mg nightly but schedule a follow-up visit or telehealth check at 8 weeks to confirm absence of breakthrough bleeding. Breakthrough bleeding at this stage warrants transvaginal ultrasound to assess endometrial thickness. An endometrial stripe above 4 mm in a postmenopausal woman on continuous combined therapy should prompt biopsy referral per the 2022 Endocrine Society guidelines [5].

Cyclic Regimen (200 mg Nightly, 12 to 14 Days per Month)

Cyclic progesterone timing matters. If the illness interrupted a mid-cycle progesterone course, the prescriber should assess which cycle day the patient was on when therapy stopped.

• Stopped before day 7 of the progesterone phase: restart the full 12-to-14-day course from day 1.
• Stopped on day 7 or later: complete the interrupted course by resuming and finishing the remaining days, then resume normal cycling the following month.
• Interruption spanned an entire calendar month: run one complete 14-day course before returning to standard scheduling, to ensure adequate monthly endometrial protection [4].

Dose Adjustment for Hepatic Recovery

If the acute illness involved significant hepatic involvement (transaminases elevated above 3x ULN at peak), restart should be deferred until transaminases return to below 2x ULN. At that point, starting at 50% of the usual dose for the first 7 nights, then returning to standard dosing, reduces the risk of allopregnanolone accumulation and excessive sedation. A 2020 review in Clinical Pharmacokinetics confirmed that CYP3A4 impairment increases progesterone metabolite exposure in a dose-dependent manner [3].

Drug Interactions Relevant to Post-Illness Restart

Acute illness often introduces new medications. Several classes interact with oral micronized progesterone in ways that matter clinically.

Antibiotics and CYP3A4 Inducers

Rifampin (rifampicin), commonly used for tuberculosis or staphylococcal decolonization, is a potent CYP3A4 inducer. Co-administration reduces oral progesterone AUC by approximately 60%, potentially rendering standard doses insufficient for endometrial protection [2]. If a patient received or is continuing rifampin, consider switching to vaginal progesterone (which bypasses first-pass metabolism) rather than increasing the oral dose.

Antifungals and CYP3A4 Inhibitors

Fluconazole, frequently prescribed for Candida infections secondary to antibiotic courses during illness, inhibits CYP3A4 and can increase progesterone exposure [2]. At standard fluconazole doses (150 mg single dose or short course), the interaction is likely subclinical. A 5-to-7-day course at 200 mg daily, however, could meaningfully raise allopregnanolone levels and increase sedation. Patients should be counseled about this effect and advised not to drive within 4 to 6 hours of the progesterone dose while on concurrent azole antifungals.

Sedatives and GABA-Ergic Agents

Benzodiazepines, non-benzodiazepine hypnotics (zolpidem), and gabapentinoids prescribed during hospitalization can produce additive CNS depression with allopregnanolone. On restart, confirm that acute sedatives have been discontinued or reduced before returning to the full progesterone dose, particularly in older patients or those with baseline sleep-disordered breathing [3].

Monitoring After Restart

Endometrial Surveillance

The North American Menopause Society (NAMS) recommends that any postmenopausal woman on estrogen-progestogen therapy who experiences unexpected bleeding undergo evaluation, including transvaginal ultrasound, regardless of whether her HRT was interrupted [8]. Post-illness breakthrough bleeding should never be attributed solely to the progesterone interruption without ruling out endometrial pathology.

Endometrial thickness below 4 mm on transvaginal ultrasound has a negative predictive value of 99% for endometrial cancer in postmenopausal women experiencing bleeding, per a meta-analysis of 35 studies (N=5,892) published in Obstetrics and Gynecology [9].

Symptom Reassessment at 4 Weeks

Post-illness patients often return to clinic with altered symptom profiles. Vasomotor symptoms may have worsened if estrogen was also interrupted. Sleep disruption from the allopregnanolone effect may have changed. A structured 4-week follow-up call or visit should assess:

• Frequency and severity of hot flashes (modified Kupperman Index or MRS score)
• Sleep quality (subjective, or Pittsburgh Sleep Quality Index for formal scoring)
• Any new spotting or breakthrough bleeding
• CNS side effects: dizziness, excessive daytime sedation

Lab Monitoring

Routine serum progesterone levels are not required for monitoring efficacy of oral micronized progesterone in HRT, because the endometrial effect is local and the sedative effect correlates with allopregnanolone, not progesterone itself [5]. However, in patients who had a hepatic illness, a repeat comprehensive metabolic panel at 4 weeks confirms hepatic recovery and guides any remaining dose adjustments.

Special Populations

Older Adults (Age 65 and Above)

Allopregnanolone accumulation from progesterone metabolism poses a fall and cognitive-impairment risk in older patients. A 2021 cohort analysis in JAGS (Journal of the American Geriatrics Society) found that older women taking oral progesterone had a modestly higher rate of next-day sedation-related falls compared with those using the vaginal route [10]. After an acute illness that involved prolonged bed rest or deconditioning, clinicians should consider switching from oral to vaginal progesterone (Endometrin 100 mg or compounded vaginal suppository) to maintain endometrial protection with less CNS exposure, at least during the recovery period.

Patients With Prior DVT or PE

Oral micronized progesterone does not carry the prothrombotic signal of synthetic progestogens, as demonstrated in the E3N cohort [7]. Still, the 2019 ACOG Committee Opinion No. 778 on hormone therapy in women with a history of VTE recommends individualized risk-benefit assessment before any progestogen restart after an acute VTE event, regardless of progestogen type [11]. In this population, restart should involve shared decision-making and, if clinically appropriate, consultation with hematology to confirm adequate anticoagulation before resuming.

Patients With Peanut Allergy

Prometrium capsules contain peanut oil. Acute illness sometimes unmasks or worsens atopic conditions. Before restart, explicitly confirm that no new peanut sensitivity has developed. If allergy status is uncertain, compounded micronized progesterone in a non-peanut carrier (sesame oil or olive oil) is a pharmacologically equivalent alternative [1].

Patient Communication Points

Clear patient instructions reduce post-illness restart errors. Three specific points should be communicated at every post-illness follow-up.

First, the patient should take Prometrium at bedtime with a small snack, even during illness recovery when appetite is reduced. Even 4 to 6 crackers with the capsule meaningfully improves fat-assisted absorption compared with fasting [2].

Second, the patient should not double-dose to compensate for missed nights. Because the endometrial protective effect of progesterone accumulates over 12 to 14 days of continuous exposure rather than via a single high dose, doubling up provides no additional benefit and increases the risk of next-day sedation [4].

Third, any spotting or bleeding that starts within the first two weeks of restart should prompt a call to the clinic rather than waiting for the scheduled follow-up, because early evaluation simplifies triage and avoids delay in identifying any endometrial pathology that may have developed during the interruption.